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StructureVertebral fractures and trabecular bone loss are hallmarks of osteoporosis. However, 80% of fractures are non-
vertebral and 70% of all bone loss is cortical and is produced by intracortical remodeling. The resulting cortical
porosity increases bone fragility exponentially. Denosumab, a fully human anti-RANKL antibody, reduces the
rate of bone remodeling more than alendronate. The aim of this study was to quantify the effects of denosumab
and alendronate on cortical and trabecular bone. Postmenopausal women, mean age 61 years (range 50 to 70),
were randomized double blind to placebo (n = 82), alendronate 70 mgweekly (n = 82), or denosumab 60 mg
every 6 months (n = 83) for 12 months. Porosity of the compact-appearing cortex (CC), outer and inner cortical
transitional zones (OTZ, ITZ), and trabecular bone volume/total volume (BV/TV) of distal radius were quantiﬁed
in vivo from high-resolution peripheral quantitative computed tomography scans. Denosumab reduced remod-
eling more rapidly and completely than alendronate, reduced porosity of the three cortical regions at 6 months,
more so by 12 months relative to baseline and controls, and 1.5- to 2-foldmore so than alendronate. The respec-
tive changes at 12 months were [mean (95% CI)]; CC:−1.26% (−1.61,−0.91) versus−0.48% (−0.96, 0.00),
p = 0.012; OTZ:−1.97% (−2.37,−1.56) versus−0.81% (−1.45,−0.17), p = 0.003; and ITZ:−1.17% (−1.38,
−0.97) versus−0.78% (−1.04,−0.52), p = 0.021. Alendronate reduced porosity of the three cortical regions
at 6 months relative to baseline and controls but further decreased porosity of only the ITZ at 12 months. By 12 -
months, CC porosity was no different than baseline or controls, OTZ porosity was reduced only relative to baseline,
not controls, while ITZ porosity was reduced relative to baseline and 6 months, but not controls. Each treatment
increased trabecular BV/TV volume similarly: 0.25% (0.19, 0.30) versus 0.19% (0.13, 0.30), p = 0.208. The greater
reduction in cortical porosity by denosumab may be due to greater inhibition of intracortical remodeling. Head
to head studies are needed to determine whether differences in porosity result in differing fracture outcomes.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.c.
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174 R.M. Zebaze et al. / Bone 59 (2014) 173–179IntroductionAll genetic and environmental factors inﬂuencing bone's material
and structural strength express their effects through the ﬁnal common
pathway of bone modeling and remodeling [1]. During young adult-
hood, this cellular machinery maintains bone's material composition
and microstructure by replacing a volume of old or damaged bone
with an equal volume of new bone; no permanent bone loss or structur-
al deterioration occurs [2,3]. As age advances, and especially after
menopause, remodeling becomes unbalanced and accelerated; large
numbers of remodeling units, each depositing a smaller volume of
bone than they remove, cause structural deterioration [2]. Remodeling
upon trabecular surfaces thins and disconnects trabeculae. Remodeling
upon endocortical surfaces thins the cortexwhile intracortical remodel-
ing upon themyriads of Haversian canals enlarges them focally, increas-
ing porosity [3]. Intense intracortical remodeling in the inner third of
the cortex adjacent to the medullary canal produces large intracortical
pores and cortical fragments that occupy a ‘transitional zone’ between
the compact-appearing but increasingly porous cortex and the trabecu-
lar compartment.
To inhibit remodeling, antiresorptive agents must either prevent os-
teoclastogenesis or access existing remodeling sites and reduce resorp-
tive activity or the longevity of osteoclasts already formed and resorbing
bone [4]. Antiresorptive efﬁcacy alsomay depend on the accessibility of
treatments to the site being remodeled. Trabeculae are thin plates in
close contact with vascular spaces. These plates have a large surface
area allowing the adsorption of bisphosphonates into trabecular bone
matrix so that bisphosphonate is present in high concentration [5–7].
When osteoclasts excavate and engulf trabecular bone matrix they are
likely to also engulf bisphosphonate and inhibit remodeling [4].
Inhibiting intracortical remodeling may be more challenging be-
cause cortical bone has less surface area per unit volume of mineralized
bone matrix upon which bisphosphonates can be adsorbed. Less bis-
phosphonate may be incorporated into the large mineralized cortical
bone matrix volume resulting in lower bisphosphonate concentrations
than in trabecular bone matrix [8]. When osteoclasts tunnel through
cortical bone theymay be less likely to encounter bisphosphonatewith-
in the matrix they engulf so remodeling continues.
Denosumab, a fully human monoclonal antibody, binds to RANKL
and prevents its bindingwith RANK receptors on osteoclasts and osteo-
clast precursors and so inhibits the synthesis, activity, and lifespan of
existing osteoclasts [9–11]. It is not bound to bone and so is widely dis-
tributed throughout the skeleton [12]. It inhibits remodeling and re-
duces porosity to a greater extent than alendronate in non-human
primates [13]. Inmice, osteoprotegerin (OPG), the endogenous inhibitor
of RANKL, reduces porosity and preserves bone strength more than ei-
ther alendronate or zoledronic acid [14].
Both cortical and trabecular bone determine bone strength; 80% of
fractures in women over 65 years are non-vertebral [15], 80% of bone
is cortical, and 70% of all appendicular bone loss is cortical and occurs
mainly by intracortical remodeling [3]. The resulting increase in
intracortical porosity reduces bone strength exponentially [3]. We hy-
pothesized that the greater inhibition of remodeling with denosumab
in postmenopausal womenwill result in a greater reduction in porosity
than achieved using alendronate, while effects on trabecular bone will
not differ.
Methods
The design and primary results of the study are published [11]. This
was a 12-month, randomized, double-blind, double-dummy study of
247 postmenopausal women aged 61 ± 5 years with lumbar spine
or total hip bone mineral density (BMD) T-score between −2.0 and
−3.0 SD assessed using dual-energy X-ray absorptiometry. Treatments
were denosumab 60 mgevery 6 months, alendronate 70 mgweekly, or
placebo. Of the 247 subjects randomized, 146 had results atmonth 12 asmeasured by StrAx1.0 software. Missing data was due to movement ar-
tifacts or missing serial measurements. The threshold for exclusion of
images due to motion artifact is lower than when measuring other pa-
rameters such as density. The exclusion of images because of artifacts
was done blind to treatment allocation. There were no baseline demo-
graphic, biochemical, or densitometric differences between subjects
with or without available data and the entire cohort. All subjects re-
ceived calcium (≥500 mg/day) and vitamin D supplements based on
serum 25-hydroxyvitamin D (25[OH]D) at screening. The daily dose
was ≥400 IU if 25[OH]D was N20 ng/mL (N50 nmol/L) or ≥800 IU if
25[OH]D was 12 to 20 ng/mL (30 to 50 nmol/L).
Women were included if high-resolution peripheral computed to-
mography (HR-pQCT, XtremeCT®) could be performed on at least one
wrist. Exclusion criteria were: a fragility fracture after age 50 years, a
prevalent moderate to severe vertebral deformity (semiquantitative
criteria); 25[OH]D b 12 ng/mL; conditions affecting bone metabolism;
contraindications to alendronate; prior intravenous bisphosphonate;
ﬂuoride (except for dental procedures), or strontium ranelate; cumula-
tive oral bisphosphonate ≥3 months; bisphosphonate for ≥1 month
within the past year, any use within 3 months of randomization; para-
thyroid hormone use within 12 months; or other drugs known to affect
bone remodeling or density within 3 months of randomization. The in-
stitutional review board or ethics committee at each site approved the
study. The study was conducted in accordance with all country regula-
tions, the Declaration of Helsinki, and the International Conference on
Harmonization Good Clinical Practice Guidelines. All subjects provided
written informed consent prior to enrollment.
Ultradistal radius images were acquired using Scanco HR-pQCTwith
an isotropic voxel size of 82 μm [16,17]. Cortical porositywas quantiﬁed
at baseline, 6 and 12 months using StrAx1.0, a software able to automat-
ically quantify the porosity within the compact-appearing cortex and
the outer and inner transitional zones of the cortex [18,19]. The outer
transitional zone is trabecularized cortex adjacent to the compact-
appearing cortex, while the inner transitional zone is trabecularized
cortex adjacent to the medullary cavity [19].
StrAx1.0 is available as an online image analysis software (www.
straximages.com). The method is accurate in measuring dimensions
(total cross-sectional area, areas of compact-appearing cortex, transi-
tional zones, and trabecular compartments) and porosity. The regres-
sion between the gold standard micro-CT and StrAx1.0 measurements
from HRpQCT has an R2 ranging from 0.87 to 0.99. The regression
between gold standard scanning electron microscopy (SEM) and
StrAx1.0 measurements from HRpQCT images has an R2 ranging from
0.91 to 0.99 for areas and porosity. Reproducibility expressed as the
root mean square of the coefﬁcient variation (RMS CV%) for areas and
porosity measurements ranges from 0.54 to 3.98% [18]. Porosity was
quantiﬁed as the percent of the total compartment volume occupied
by void. Details and validation of themethod of quantiﬁcation of poros-
ity using StrAx1.0 are published [16,18–21]. To avoid overestimating
porosity by including under-mineralized bone matrix, quantiﬁcation
of porosity is conﬁned to voxels with attenuation values less than 80%
of that produced by fully mineralized bone. Voxels with attenuation
values greater than 80% of that produced by fully mineralized bone
were excluded from the analysis because pores only produce attenua-
tion below 80% of maximum [19]. Voxels producing attenuation within
80% of maximum contain matrix that has undergone incomplete sec-
ondary mineralization (primary mineralization reaches 80% of maxi-
mum within a few days of matrix deposition). Thus, there is little, if
any confounding effect of mineralization.
Because StrAx1.0 quantiﬁes porosity from all pores including those
below the nominal voxel size of theHRpQCT (82 μm), themeasurement
is sensitive to artifacts such as those introduced bymotion. Images with
motion artifacts were excluded without knowledge of treatment
allocation.
Analyses were performed on all subjects with data with no imputa-
tion for missing data and were reported as change from baseline. The
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Density estimates were derived using a kernel density estimator with
a Gaussian kernel using Silverman's approach for selecting bandwidth
[22]. Estimates for the changes in porosity and inferential statistics
were derived using a random intercept model with subject as the ran-
dom effect with main effects for treatment, visit, and baseline porosity
[23]. The model included interactions between treatment and visit
and between baseline porosity and visit. The model allowed for hetero-
geneity in variance between treatments. Analyses were performed
using R version 2.15.0 [24]. The mixed effects models were ﬁt using
the nlme package [25].
This study was the ﬁrst to use porosity as an outcome variable and
therefore nopower calculations could be done a priori as no preliminary
data were available. We conducted a post-hoc evaluation of power
from the observed responses. Power ranged from approximately 60%
(compact-appearing cortex) to N90% (inner and outer transitional
zones and trabecular BV/TV) for the observed alendronate effects and
were even larger for the observed denosumab effects.We note however
that any statement of post-hoc power needs to be interpretedwith cau-
tion in the context of a completed study [26].Results
Baseline characteristics for subjects with evaluable 12-month poros-
ity data are shown in Table 1 andwere similar among treatment groups.
As shown in Fig. 1, baseline mean and frequency distribution curves of
serum CTX did not differ by group. Serum CTX decreased in all groups
at 3 months, shifting the distribution of individual values such that
there was overlap between alendronate-treated women and controls
(who received calcium and vitamin D) but little overlap between
denosumab-treated women and controls.
Denosumab reduced porosity of the compact-appearing cortex, the
outer and inner transitional zones relative to baseline and controls,
but not signiﬁcantly relative to the alendronate group at 6 months
(Fig. 2). By 12 months, denosumab reduced porosity at all three cortical
regions relative to baseline, 6 months, controls, and alendronate-
treated subjects. The reduction in porosity was 1.5- to 2-fold greater
than achieved by alendronate throughout the cortex; respectively,
compact-appearing cortex: −1.26% (95% CI −1.61, −0.91) versus
−0.48% (95% CI −0.96, 0.00), p = 0.012; outer transitional zone:
−1.97% (95% CI−2.37,−1.56) versus−0.81% (95% CI−1.45,−0.17),
p = 0.003; and inner transitional zone:−1.17% (95% CI−1.38,−0.97)Table 1
Baseline characteristics.
Placebo
N = 54
Alendronate
N = 40
Denosumab
N = 52
Age 61.2 (5.3) 60.0 (5.0) 60.3 (6.1)
Area (mm2)
Trabecular 133.87 (28.02) 132.82 (33.85) 125.56
(25.92)
Inner transitional zone 32.92 (6.08) 32.79 (7.40) 30.81 (5.72)
Outer transitional zone 7.71 (0.89) 7.56 (1.18) 7.70 (1.02)
Compact-appearing cortex 38.97 (6.71) 38.22 (7.04) 38.84 (6.70)
Percent of total cortical volume
occupied by porosity
39.8 (8.1) 40.8 (9.6) 38.3 (8.2)
Inner transitional zone 79.0 (3.3) 79.7 (3.2) 78.6 (3.7)
Outer transitional zone 17.3 (6.4) 18.3 (7.3) 17.3 (6.3)
Compact-appearing cortex 11.5 (6.4) 12.6 (7.8) 10.7 (5.9)
Distal radius BMD T-score −1.5 (1.1) −1.8 (0.7) −1.9 (0.9)
Femoral neck BMD T-score −1.5 (0.7) −1.8 (0.6) −1.7 (0.7)
Total hip BMD T-score −1.1 (0.8) −1.3 (0.7) −1.3 (0.8)
sCTX, ng/mL, median (IQR) 0.8 (0.6, 0.9) 0.8 (0.6, 0.9) 0.7 (0.5, 0.8)
N = number of subjects with evaluable 12-month porosity data. Data are mean (SD) un-
less otherwise indicated.versus −0.78% (95% CI −1.04, −0.52), p = 0.021. Denosumab also
produced a more homogeneous response (lower variability) compared
with alendronate at the compact-appearing cortex and outer transition-
al zone.
Alendronate reduced porosity in the compact-appearing cortex,
the outer and inner transitional zones relative to baseline and controls
at 6 months. Porosity of the compact-appearing cortex and outer transi-
tional zone did not decrease further between 6 and 12 months, but
did so only for the inner transitional zone. By 12 months, compact-
appearing cortical porosity in the alendronate group was no lower
than baseline or controls. Porosity of the outer transitional zone was
lower than baseline, not controls, while porosity of the inner transition-
al zone was lower than at baseline and 6 months but not controls (in
whom it decreased).
In multivariate analyses, treatment with denosumab was the stron-
gest predictor of the reduction in cortical porosity, independent of base-
line remodeling determined by serumCTX. Improvements in trabecular
BV/TV with denosumab and alendronate were signiﬁcant relative to
baseline and controls (both p ≤ 0.001) and did not differ from each
other: 0.25% (95% CI 0.19, 0.30) versus 0.19% (95% CI 0.13, 0.30), respec-
tively, p = 0.208 (Fig. 2).
Discussion
We report that (i) denosumab reduced remodeling more rapidly
and more completely than alendronate as assessed by serum CTX.
By 3 months, women receiving denosumab and controls had almost
complete separation of their serum CTX frequency distribution curves
whereas the curve for women receiving alendronate overlapped that
of controls. (ii) Denosumab reduced porosity at 6 months, further by
12 months, and did so more than alendronate. (iii) Alendronate de-
creased porosity at 6 months but no further by 12 months in the
compact-appearing and outer transitional zones. By 12 months, cortical
porosity with alendronate was no different from controls.
These ﬁndings conﬁrm and extend the previously reported decrease
in remodeling, and cortical porosity in cynomolgus monkeys treated
with denosumab [27]. Antiresorptives slow the rate of bone remodeling
which in turn slows the worsening of porosity, but does not actually re-
duce porosity. We propose that the reduction in porosity seen with
denosumab is the net result of two processes. At the start of therapy, re-
sorption rapidly ceases in existing cavities and they proceed with their
slower reﬁlling phase. As these sites reﬁll, denosumab simultaneously
virtually abolishes the birth of new excavation sites producing a net re-
duction in porosity [27]. Remodeling remains suppressed until remodel-
ing sites reappear shortly before the second injection. With the second
injection, resorption at these sites is again stopped, the sites enter
their reﬁlling phase while once again, few if any new remodeling sites
appear as this second dose again abolishes osteoclastogenesis. Porosity
decreases further and is lower than at 6 months, lower than at baseline,
lower than in controls, and lower than in the alendronate group.
In alendronate-treated subjects, resorption cavities excavated
shortly before treatment also reﬁll but, by contrast, as alendronate
only reduces remodeling by 50–60% [28,29], reﬁlling is offset by the
appearance of the residual 40–50% remodeling that is not inhibited
by alendronate so the net reduction in porosity is less than with
denosumab. These residual remodeling sites excavated during the ﬁrst
6 months enter their reﬁlling phase in the second 6 months but this
reﬁlling is nowoffset by at least an equal number of newly excavated re-
modeling sites so that there is no further net reduction in porosity be-
tween 6 and 12 months. Porosity at 12 months was no lower than at
6 months andwas no longer signiﬁcantly lower than controls given cal-
cium and vitaminD (which also reduced remodelingmarkers as seen by
the shift in the serum CTX frequency distribution curve). Thus, a reduc-
tion in porosity by 12 months in the compact-appearing cortex and
outer transitional zone was observed with denosumab but not with
alendronate. In the inner transitional zone, a greater reduction in
Fig. 1. Frequency distribution curves for serum C-telopeptide of cross-linked collagen (CTX) at baseline and 3 months in controls, alendronate, and denosumab-treated women. After
3 months, there was little overlap between denosumab-treated women and controls receiving calcium and vitamin D while there was substantial overlap between alendronate-
treated women and controls. The curves at month 3 are truncated at log (0.052 ng/mL), which represents the lower quantiﬁable limit of the assay.
176 R.M. Zebaze et al. / Bone 59 (2014) 173–179porosity with denosumab than alendronate was observed and porosity
in the alendronate groupwas not different to porosity in controls. In the
trabecular compartment, the improvement in BV/TV produced by each
drug was similar.
We suggest that this regional speciﬁcity may, in part, be a func-
tion of the architecture of the bone itself. Remodeling is surfaceFig. 2. The top image shows three-dimensional reconstruction of the distal radiuswith the comp
ular compartment (yellow). Middle images show each of the regions segmented and reconstru
ume fraction at baseline, 6, and 12 months in controls, alendronate, and denosumab-treated sdependent [30,31]. Bisphosphonates adsorb upon a surface and bind
to subendosteal mineralized bone matrix. Cortical bone has a low sur-
face area/mineralized bone matrix volume; there is less surface per
unit mineralized bone matrix volume for alendronate to be adsorbed
upon. Trabecular bone is fashioned as plates with a large surface area/
bone matrix volume conﬁguration and trabecularized cortex also has aact-appearing cortex (green), outer (white) and inner (red) transitional zone, and trabec-
cted and the graphs show the corresponding changes in porosity and trabecular bone vol-
ubjects. p b 0.05 compared with: abaseline, bmonth 6, ccontrol, and dalendronate.
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cortex. Concentrations of bisphosphonate are lower in cortical than tra-
becular bone [8]. Osteoclasts excavating a canal deepwithin cortical ma-
trix may be less likely to encounter alendronate within matrix allowing
them to continue to resorb bone andproduce porosity despite treatment
(Fig. 3, lower panels). By contrast, denosumab circulates freely to bone
surfaces and into remodeling compartments within which it inhibits os-
teoclastogenesis and so can inhibit remodeling more rapidly and mark-
edly than alendronate in cortical bone, an observation supported by
the near complete reduction in bone resorptionmarkers [9,12,27,32,33].
The inner transitional zone is adjacent to themarrow cavity and con-
tains trabecularized cortex and trabeculae.We suggest that alendronate
has greater access to remodeling sites in the inner transitional zone than
in the compact-appearing cortex. Alendronate is easily adsorbed upon
trabecular surfaces and distributes within the relatively smaller miner-
alized bone matrix volume so that actively-resorbing osteoclasts are
likely to encounter and engulf bone matrix containing alendronate
and so be inhibited upon trabecular surfaces [4,34]. Both drugs allow
reﬁlling of excavated trenches upon trabecularized cortex and trabecu-
lae with similar reductions in new remodeling sites.
To explain these observations, we speculate that the 50 to 60% re-
duction in serum CTX with alendronate represents the net result of a
near complete reduction in remodeling of trabecular bone but much
less of an effect upon the deeper cortical surfaces. This would explain
the lesser effect of alendronate on cortical porosity but similar beneﬁts
of alendronate and denosumab in trabecular bone (Fig. 3, upper panels).
It also explains the lack of improvement in cortical vBMD at the distal
radius using alendronate [9–11], but the increase in distal radius BMD
consistently observed with denosumab [35–37].
Preclinical studies support these observations. In a mouse model
with high cortical remodeling, OPG, the endogenous inhibitor of
RANKL, reduced porosity and improved bone strength whereas largerFig. 3. Remodeling is initiatedwithin bone remodeling compartments (BRCs) at points beneath t
(lower panels). Osteoclast precursors differentiate into bone-resorbing osteoclasts within BRCs
engulf matrix containing alendronate, and denosumab accesses osteoclasts via the extracellular
alendronate and so resorb bone but denosumab accesses BRCs as freely as it does in trabeculardoses of alendronate and zoledronic acid than used clinically had lesser
effects on porosity and strength. This cannot be explained by differences
in drug dosages as the beneﬁts of OPG and the bisphosphonates were
similar at trabecular sites [14]. Similarly, OPG reduced cortical porosity
more greatly than zoledronic acid in a rat model of adjuvant arthritis,
and denosumab reduced cortical porosity more than alendronate in
nonhuman primates [13,38].
Further distinctions between the treatments may be relevant. The
earlier and more complete inhibition of remodeling by denosumab is
also likely to be the result of rapid and full inhibition of the activity
and life span of osteoclasts in remodeling sites existing at the time of
treatment [39]. This would produce a more shallow resorption cavity
which may then be more completely reﬁlled by the ensuing bone for-
mation, reducing structural decay [34]. Bisphosphonates do not prevent
osteoclastogenesis. To inhibit remodeling, bisphosphonates must ﬁrst
be adsorbed upon the endosteal surface and bind to matrix which is
then engulfed by osteoclasts, following which, resorptive activity is
inhibited. Thus, some erosion must occur before bisphosphonates can
stop resorption.
If these observations are correct, they are of potential clinical signif-
icance. While vertebral fractures and trabecular bone loss are hallmarks
of osteoporosis [1,40,41], non-vertebral fractures account for 80% of all
fractures [15]. Cortical bone is remodeled more slowly than trabecular
bone, but across life, cortical bone loss is 2 to 3 times greater than tra-
becular bone loss in absolute terms because the skeleton is 80% cortical;
only 20% is trabecular [3]. About 70% of all appendicular bone loss is cor-
tical and occurs by intracortical remodelingwhich increases porosity, an
important cause of susceptibility to non-vertebral fractures. A small in-
crease in porosity disproportionately reduces resistance to bending; this
is more so in cortical than trabecular bone [42,43].
Non-vertebral anti-fracture reduction is 20 to 30%, less than half the
vertebral fracture risk reduction reported in most trials [44]. Onehe canopy of cells lining trabecular bone (upper panels) and cortical boneHaversian canals
. In trabecular bone, alendronate and denosumab inhibit resorption similarly; osteoclasts
ﬂuid. In cortical bone, osteoclasts encounter little peri-Haversian canal matrix containing
bone.
178 R.M. Zebaze et al. / Bone 59 (2014) 173–179explanationmay be the differing access of drugs to intracortical remod-
eling sites initiated upon Haversian canals within the large cortical
matrix volume [4,34]. Risedronate has a lower mineral binding afﬁnity
than alendronate and penetrates deeper into cortical bone [4,34].
Risedronate reduced non-vertebral fracture rates in two of the three
main trials [45–47], while alendronate did not [48,49]. Nakamura
et al. reported that in a 24-month study of 1194 postmenopausal
Japanese women and men (placebo, n = 480; denosumab 60 mg
every 6 months, n = 472; or open-label alendronate 35 mg weekly,
n = 242) [50], new or worsening vertebral fractures occurred in 8.5%,
2.4%, and 5.0% of women, respectively (p = 0.0001 denosumab versus
placebo). Major non-vertebral fractures occurred in 3.9%, 1.7%, and
2.3% of women, respectively (p = 0.057, denosumab versus placebo).
Thus, numerically, fewer fractures occurred in the denosumab
than alendronate group but statistical analyses comparing the two
antiresorptives was not reported. Moreover, women treated with
denosumab in the pivotal phase 3 trial, although a placebo comparator
armwas not available in the 4th and 5th years, had a low reported non-
vertebral fracture rate, an observation not reported for alendronate or
zoledronic acid, the latter also having high afﬁnity for bonemineral [51].
This study has limitations. StrAx1.0 analysis does not quantify pore
size and number so that the relative contribution of reductions in pore
number versus pore size to the reduction in porosity cannot be deter-
mined at this time. Measures of porosity using StrAx1.0 are more sensi-
tive thanmeasures of density tomotion artifacts and this resulted in loss
of some images.
In summary, this is the ﬁrst randomized double-blind, placebo con-
trolled trial comparing the effect of two remodeling suppressant thera-
pies on intracortical porosity in vivo. Denosumab reduced remodeling
more rapidly, more completely and decreased porosity more than
alendronate. Given the exponential relationship between porosity and
bone stiffness, partly reversing cortical porosity is likely to contribute
to reductions in fracture risk.Whether this greater reduction in porosity
translates into better anti-fracture efﬁcacy will require additional com-
parator trials.Disclosures
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